title: Adding 11C-methionine PET to the EORTC prognostic factors in grade 2 gliomas.
abstract: OBJECTIVE
  The management of adult patients with grade 2 gliomas remains a challenge for the clinical neuro-oncologist. Several clinical prognostic factors appear to be as important as treatment factors in determining outcome. From the European Organisation for Research and Treatment of Cancer (EORTC) trials 22844 and 22845, a prognostic scoring system has been proposed based on the presence of unfavourable prognostic factors. The aim of the present study was to assess the additional prognostic value of (11)C-methionine (MET) measured by positron emission tomography (PET) in the setting of the EORTC prognostic scoring system.
  
  
  METHODS
  In this retrospective review, 129 patients with supratentorial grade 2 gliomas were subjected to a PET study as part of the pre-treatment tumour investigation. One hundred and three cases were classified as low-risk patients (0-2 unfavourable factors) and 26 cases as high-risk patients (3-5 unfavourable factors) according to the EORTC criteria. MET PET was evaluated as an extra prognostic factor in both groups.
  
  
  RESULTS
  In the high-risk group, patients with high MET uptake had a worse outcome than patients with low MET uptake. A similar trend was found for the low-risk group in patients with oligodendrocytic tumours.
  
  
  CONCLUSIONS
  Our findings further strengthen the role of MET PET as an important prognostic tool in the management of this group of patients.
authors: Department of Neuroscience, Neurology, University Hospital, 751 85, Uppsala, Sweden. anja.smits@neurologi.uu.se
authors: A
authors: A
authors: Smits
authors: E
authors: E
authors: Westerberg
authors: D
authors: D
authors: Ribom
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002250:Carbon Radioisotopes; D005910:Glioma / Q000175:diagnosis* / Q000000981:diagnostic imaging / Q000473:pathology* / Q000601:surgery; D006801:Humans; D008715:Methionine / Q000737:chemistry* / Q000378:metabolism; D008875:Middle Aged; D049268:Positron-Emission Tomography; D011184:Postoperative Period; D011379:Prognosis; D012189:Retrospective Studies; D012306:Risk; D012955:Societies, Medical; D015996:Survival Rate
chemical_list: D002250:Carbon Radioisotopes; D008715:Methionine
references: Cancer. 2001 Sep 15;92 (6):1541-9
references: 11745233
references: J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9
references: 11895036
references: Br J Neurosurg. 2002 Dec;16(6):573-7
references: 12617239
references: Cancer. 1994 Sep 15;74(6):1784-91
references: 8082081
references: Acta Radiol. 1987 May-Jun;28(3):225-9
references: 2958026
references: Int J Radiat Oncol Biol Phys. 1999 Nov 1;45(4):923-9
references: 10571199
references: J Neurosurg. 2001 Nov;95(5):735-45
references: 11702861
references: J Clin Oncol. 2002 May 1;20(9):2267-76
references: 11980997
references: J Clin Oncol. 2002 Apr 15;20(8):2076-84
references: 11956268
references: J Neurosurg. 2006 Feb;104(2):238-53
references: 16509498
references: Onkologie. 2004 Jun;27(3):246-50
references: 15249713
references: Neurology. 1998 May;50(5):1316-22
references: 9595980
references: Int J Radiat Oncol Biol Phys. 1996 Oct 1;36(3):549-56
references: 8948338
references: Neurology. 2002 Jul 9;59(1):40-8
references: 12105305
references: J Neurosurg. 2001 Nov;95(5):746-50
references: 11702862
references: Neurology. 2002 Jul 9;59(1):121-3
references: 12105319
references: Eur J Nucl Med Mol Imaging. 2002 May;29(5):632-40
references: 11976801
references: Curr Opin Neurol Neurosurg. 1992 Dec;5(6):924-31
references: 1334739
references: Semin Oncol. 2003 Dec;30(6 Suppl 19):23-8
references: 14765381
references: Acta Neuropathol. 2005 Jan;109(1):93-108
references: 15685439
references: Neurology. 2000 Apr 11;54(7):1442-8
references: 10751254
references: Neurology. 2001 May 22;56(10):1285-90
references: 11376174
references: Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):316-24
references: 11872276
references: J Nucl Med. 1998 May;39(5):778-85
references: 9591574